Maryland State Retirement & Pension System raised its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 13.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 108,184 shares of the company’s stock after buying an additional 12,825 shares during the quarter. Maryland State Retirement & Pension System’s holdings in AbbVie were worth $28,300,000 at the end of the most recent quarter.
A number of other hedge funds have also recently modified their holdings of the business. Ritholtz Wealth Management increased its stake in shares of AbbVie by 23.0% during the third quarter. Ritholtz Wealth Management now owns 60,877 shares of the company’s stock valued at $15,925,000 after purchasing an additional 11,390 shares in the last quarter. UNIVEST FINANCIAL Corp boosted its position in shares of AbbVie by 6.7% in the 3rd quarter. UNIVEST FINANCIAL Corp now owns 7,325 shares of the company’s stock worth $1,916,000 after purchasing an additional 459 shares in the last quarter. Granville Capital Inc. boosted its position in shares of AbbVie by 12.8% in the 3rd quarter. Granville Capital Inc. now owns 1,345 shares of the company’s stock worth $352,000 after purchasing an additional 153 shares in the last quarter. Joel Isaacson & Co. LLC boosted its position in shares of AbbVie by 2.7% in the 3rd quarter. Joel Isaacson & Co. LLC now owns 8,927 shares of the company’s stock worth $2,335,000 after purchasing an additional 233 shares in the last quarter. Finally, Jacobi Capital Management LLC grew its stake in shares of AbbVie by 0.6% in the 3rd quarter. Jacobi Capital Management LLC now owns 32,871 shares of the company’s stock worth $8,599,000 after buying an additional 197 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.
Insider Transactions at AbbVie
In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company’s stock.
Wall Street Analyst Weigh In
A number of research firms recently weighed in on ABBV. Bank of America reaffirmed a “buy” rating on shares of AbbVie in a research report on Tuesday, September 8th. Sanford C. Bernstein reiterated a “market perform” rating and set a $275.00 price objective on shares of AbbVie in a research note on Monday, November 2nd. Rothschild & Co Redburn boosted their target price on AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Oppenheimer increased their target price on AbbVie from $244.00 to $258.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. Finally, Piper Sandler increased their target price on AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $297.46.
Get Our Latest Stock Analysis on ABBV
AbbVie Price Performance
ABBV stock opened at $294.93 on Thursday. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $302.93. The business has a fifty day moving average price of $274.15 and a 200-day moving average price of $240.18. The stock has a market capitalization of $521.33 billion, a P/E ratio of 50.76, a P/E/G ratio of 1.34 and a beta of 0.20.
AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The firm had revenue of $17.40 billion for the quarter, compared to the consensus estimate of $17.32 billion. During the same period in the prior year, the company posted $1.86 earnings per share. The company’s quarterly revenue was up 10.3% on a year-over-year basis. As a group, analysts anticipate that AbbVie Inc. will post 13.98 earnings per share for the current year.
AbbVie Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be given a $1.82 dividend. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date of this dividend is Friday, January 15th. This represents a $7.28 dividend on an annualized basis and a yield of 2.5%. AbbVie’s payout ratio is presently 119.10%.
AbbVie Company Profile
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Read More
- Five stocks we like better than AbbVie
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
